Author Belka, Claus

• 2006 | Journal Article | 
  ​ ​The membrane targeted apoptosis modulators erucylphosphocholine and erucylphosphohomocholine increase the radiation response of human glioblastoma cell lines in vitro​
  Rübel, A.; Handrick, R.; Lindner, L. H.; Steiger, M.; Eibl, H.; Budach, W. & Belka, C. et al.​ (2006) 
  Radiation Oncology, 1 art. 6​.​ DOI: https://doi.org/10.1186/1748-717X-1-6 
  ​Details  DOI 

• 2009 | Journal Article | 
  ​ ​Pharmacokinetics and biodistribution of Erufosine in nude mice - implications for combination with radiotherapy​
  Henke, G.; Lindner, L. H.; Vogeser, M.; Eibl, H.-J.; Wörner, J.; Müller, A. C. & Bamberg, M. et al.​ (2009) 
  Radiation Oncology, 4 art. 46​.​ DOI: https://doi.org/10.1186/1748-717X-4-46 
  ​Details  DOI  PMID  PMC 

• 2010 | Journal Article | 
  ​ ​The Akt-inhibitor Erufosine induces apoptotic cell death in prostate cancer cells and increases the short term effects of ionizing radiation​
  Rudner, J.; Ruiner, C.-E.; Handrick, R.; Eibl, H.-J.; Belka, C. & Jendrossek, V.​ (2010) 
  Radiation Oncology, 5(108).​ DOI: https://doi.org/10.1186/1748-717X-5-108 
  ​Details  DOI 

• 2012 | Journal Article | 
  ​ ​Effects of ionizing radiation in combination with Erufosine on T98G glioblastoma xenograft tumours: a study in NMRI nu/nu mice​
  Henke, G.; Meier, V.; Lindner, L. H.; Eibl, H.; Bamberg, M.; Belka, C. & Budach, W. et al.​ (2012) 
  Radiation Oncology, 7(1) art. 172​.​ DOI: https://doi.org/10.1186/1748-717X-7-172 
  ​Details  DOI 

• 2013 | Conference Abstract
  ​ ​Bevacizumab, irinotecan, and radiotherapy versus standard temozolomide and radiotherapy in newly diagnosed, MGMT-non-methylated glioblastoma patients: First results from the randomized multicenter GLARIUS trial.​
  Herrlinger, U.; Schaefer, N.; Steinbach, J. P.; Weyerbrock, A.; Hau, P.; Goldbrunner, R. & Friedrich, F. et al.​ (2013)
  Journal of Clinical Oncology, 31(15) , Chicago, IL.
  Alexandria​: Amer Soc Clinical Oncology.
  ​Details  WoS 

• 2014 | Conference Abstract
  ​ ​Survival and quality of life in the randomized, multicenter GLARIUS trial investigating bevacizumab/irinotecan versus standard temozolornide in newly diagnosed, MGMT-non-methylated glioblastoma patients​
  Herrlinger, U.; Schaefer, N.; Steinbach, J. P.; Weyerbrock, A.; Hau, P.; Goldbrunner, R. & Friedrich, F. et al.​ (2014)
  Journal of Clinical Oncology, 32(15) ​50th Annual Meeting of the American-Society-of-Clinical-Oncology​, Chicago, IL.
  Alexandria​: Amer Soc Clinical Oncology.
  ​Details  WoS 

• 2015 | Journal Article | Research Paper
  ​ ​HSP90 inhibition as a means of radiosensitizing resistant, aggressive soft tissue sarcomas​
  Ernst, A.; Anders, H.; Kapfhammer, H.; Orth, M.; Hennel, R.; Seidl, K. & Winssinger, N. et al.​ (2015) 
  Cancer Letters, 365(2) pp. 211​-222​.​ DOI: https://doi.org/10.1016/j.canlet.2015.05.024 
  ​Details  DOI  PMID  PMC  WoS 

• 2016 | Journal Article
  ​ ​Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine–DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial​
  Herrlinger, U.; Schäfer, N.; Weyerbrock, A.; Hau, P.; Goldbrunner, R.; Friedrich, F. & Rohde, V.  et al.​ (2016) 
  Journal of Clinical Oncology, 34(14) pp. 1611​-1619​.​ DOI: https://doi.org/10.1200/JCO.2015.63.4691 
  ​Details  DOI  PMID  PMC  WoS 

• 2016 | Journal Article | 
  ​ ​On the analysis of clonogenic survival data: Statistical alternatives to the linear-quadratic model​
  Unkel, S.; Belka, C. & Lauber, K.​ (2016) 
  Radiation Oncology, 11 art. 11​.​ DOI: https://doi.org/10.1186/s13014-016-0584-z 
  ​Details  DOI  PMID  PMC  WoS 

• 2017 | Journal Article
  ​ ​Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma​
  Schäfer, N.; Proescholdt, M.; Steinbach, J. P; Weyerbrock, A.; Hau, P.; Grauer, O. & Goldbrunner, R. et al.​ (2017) 
  Neuro-Oncology, 20(7) pp. 975​-985​.​ DOI: https://doi.org/10.1093/neuonc/nox204 
  ​Details  DOI 

Researcher

Sort

Items per Page